{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:24:19Z","timestamp":1793863459114,"version":"4.6.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite recent progress in cancer treatment, liver metastases persist as an unmet clinical need. Here, we show that arming liver and tumor-associated macrophages in vivo to co-express tumor antigens (TAs), IFN\u03b1, and IL-12 unleashes robust anti-tumor immune responses, leading to the regression of liver metastases. Mechanistically, in vivo armed macrophages expand tumor reactive CD8<jats:sup>+<\/jats:sup> T cells, which acquire features of progenitor exhausted T cells and kill cancer cells independently of CD4<jats:sup>+<\/jats:sup> T cell help. IFN\u03b1 and IL-12 produced by armed macrophages reprogram antigen presenting cells and rewire cellular interactions, rescuing tumor reactive T cell functions. In vivo armed macrophages trigger anti-tumor immunity in distinct liver metastasis mouse models of colorectal cancer and melanoma, expressing either surrogate tumor antigens, naturally occurring neoantigens or tumor-associated antigens. Altogether, our findings support the translational potential of in vivo armed liver macrophages to expand and rejuvenate tumor reactive T cells for the treatment of liver metastases.<\/jats:p>","DOI":"10.1038\/s41467-025-58369-2","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T15:11:27Z","timestamp":1744384287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["In vivo armed macrophages curb liver metastasis through tumor-reactive T-cell rejuvenation"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-4835","authenticated-orcid":false,"given":"Marco","family":"Notaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maristella","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1840-9774","authenticated-orcid":false,"given":"Chiara","family":"Bresesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Giacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0763-5319","authenticated-orcid":false,"given":"Thomas","family":"Kerzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9599-9563","authenticated-orcid":false,"given":"Carl Mirko","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4375-004X","authenticated-orcid":false,"given":"Stefano","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-4325","authenticated-orcid":false,"given":"Marco","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Merelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Iaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0764-8163","authenticated-orcid":false,"given":"Marco","family":"Genua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-2578","authenticated-orcid":false,"given":"Andrea","family":"Annoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Cristofori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Degl\u2019Innocenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-8420","authenticated-orcid":false,"given":"Francesca","family":"Sanvito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Maria Vittoria","family":"Rancoita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-3426","authenticated-orcid":false,"given":"Renato","family":"Ostuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3517-9683","authenticated-orcid":false,"given":"Silvia","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-527X","authenticated-orcid":false,"given":"Luigi","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1188-0299","authenticated-orcid":false,"given":"Mario Leonardo","family":"Squadrito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"58369_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659964","volume":"11","author":"Y Dai","year":"2021","unstructured":"Dai, Y. et al. Perspectives on immunotherapy of metastatic colorectal cancer. Front. Oncol. 11, 659964 (2021).","journal-title":"Front. Oncol."},{"key":"58369_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100638","volume":"7","author":"MS Remond","year":"2022","unstructured":"Remond, M. S., Pellat, A., Brezault, C., Dhooge, M. & Coriat, R. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? ESMO Open 7, 100638 (2022).","journal-title":"ESMO Open"},{"key":"58369_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ccell.2021.03.004","volume":"39","author":"A Bertocchi","year":"2021","unstructured":"Bertocchi, A. et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell 39, 708\u2013724 e711 (2021).","journal-title":"Cancer Cell"},{"key":"58369_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/cmi.2016.3","volume":"13","author":"MW Robinson","year":"2016","unstructured":"Robinson, M. W., Harmon, C. & O\u2019Farrelly, C. Liver immunology and its role in inflammation and homeostasis. Cell. Mol. Immunol. 13, 267\u2013276 (2016).","journal-title":"Cell. Mol. Immunol."},{"key":"58369_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2022.02.013","volume":"40","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell 40, 424\u2013437 e425 (2022).","journal-title":"Cancer Cell"},{"key":"58369_CR6","doi-asserted-by":"crossref","unstructured":"Lee J. C. et al. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci. Immunol. 5, eaba0759 (2020).","DOI":"10.1126\/sciimmunol.aba0759"},{"key":"58369_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152\u2013164 (2021).","journal-title":"Nat. Med."},{"key":"58369_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2023.11.010","volume":"42","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell 42, 135\u2013156 e117 (2024).","journal-title":"Cancer Cell"},{"key":"58369_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"58369_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"58369_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"58369_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","volume":"42","author":"DD Klysz","year":"2024","unstructured":"Klysz, D. D. et al. Inosine induces stemness features in CAR-T cells and enhances potency. Cancer Cell 42, 266\u2013282.e268 (2024).","journal-title":"Cancer Cell"},{"key":"58369_CR13","doi-asserted-by":"crossref","unstructured":"Srivastava P. K. Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines. J. Clin. Investig. 134, e176740 (2024).","DOI":"10.1172\/JCI176740"},{"key":"58369_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.medj.2023.03.007","volume":"4","author":"E Gutierrez","year":"2023","unstructured":"Gutierrez, E. et al. An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med 4, 326\u2013340 e325 (2023).","journal-title":"Med"},{"key":"58369_CR15","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ccell.2023.09.014","volume":"41","author":"T Kerzel","year":"2023","unstructured":"Kerzel, T. et al. In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer cell 41, 1892\u20131910 e1810 (2023).","journal-title":"Cancer cell"},{"key":"58369_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.gt.3301433","volume":"8","author":"SS Diebold","year":"2001","unstructured":"Diebold, S. S., Cotten, M., Koch, N. & Zenke, M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 8, 487\u2013493 (2001).","journal-title":"Gene Ther."},{"key":"58369_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103051","volume":"138","author":"L Passeri","year":"2023","unstructured":"Passeri, L. et al. Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseases. J. Autoimmun. 138, 103051 (2023).","journal-title":"J. Autoimmun."},{"key":"58369_CR18","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.1229620","volume":"338","author":"MA Paley","year":"2012","unstructured":"Paley, M. A. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220\u20131225 (2012).","journal-title":"Science"},{"key":"58369_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra, J. C. et al. Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52, 825\u2013841 e828 (2020).","journal-title":"Immunity"},{"key":"58369_CR20","doi-asserted-by":"publisher","first-page":"8623","DOI":"10.1073\/pnas.0809818106","volume":"106","author":"SN Mueller","year":"2009","unstructured":"Mueller, S. N. & Ahmed, R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 106, 8623\u20138628 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"58369_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/cmi.2015.80","volume":"13","author":"A Ochel","year":"2016","unstructured":"Ochel, A. et al. Effective intrahepatic CD8+ T-cell immune responses are induced by low but not high numbers of antigen-expressing hepatocytes. Cell. Mol. Immunol. 13, 805\u2013815 (2016).","journal-title":"Cell. Mol. Immunol."},{"key":"58369_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/ni1469","volume":"8","author":"G Guarda","year":"2007","unstructured":"Guarda, G. et al. L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat. Immunol. 8, 743\u2013752 (2007).","journal-title":"Nat. Immunol."},{"key":"58369_CR23","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.4049\/jimmunol.2000253","volume":"205","author":"J Eberlein","year":"2020","unstructured":"Eberlein, J. et al. Chemokine signatures of pathogen-specific T cells I: effector T cells. J. Immunol. 205, 2169\u20132187 (2020).","journal-title":"J. Immunol."},{"key":"58369_CR24","doi-asserted-by":"crossref","unstructured":"Galeano Nino J. L. et al. Cytotoxic T cells swarm by homotypic chemokine signalling. Elife 9, e56554 (2020).","DOI":"10.7554\/eLife.56554"},{"key":"58369_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/019262339902700112","volume":"27","author":"BD Car","year":"1999","unstructured":"Car, B. D., Eng, V. M., Lipman, J. M. & Anderson, T. D. The toxicology of interleukin-12: a review. Toxicol. Pathol. 27, 58\u201363 (1999).","journal-title":"Toxicol. Pathol."},{"key":"58369_CR26","doi-asserted-by":"crossref","unstructured":"Siwicki M. et al. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci. Immunol. 6, eabi7083 (2021).","DOI":"10.1126\/sciimmunol.abi7083"},{"key":"58369_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse, B. et al. CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 618, 1033\u20131040 (2023).","journal-title":"Nature"},{"key":"58369_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/intimm\/dxg115","volume":"15","author":"A Kariyone","year":"2003","unstructured":"Kariyone, A. et al. Immunogenicity of Peptide-25 of Ag85B in Th1 development: role of IFN-gamma. Int. Immunol. 15, 1183\u20131194 (2003).","journal-title":"Int. Immunol."},{"key":"58369_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4049\/jimmunol.2000191","volume":"205","author":"TW Ng","year":"2020","unstructured":"Ng, T. W. et al. Exploiting pre-existing CD4(+) T cell help from bacille calmette-guerin vaccination to improve antiviral antibody responses. J. Immunol. 205, 425\u2013437 (2020).","journal-title":"J. Immunol."},{"key":"58369_CR30","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","volume":"51","author":"R Zander","year":"2019","unstructured":"Zander, R. et al. CD4(+) T cell help is required for the formation of a cytolytic CD8(+) T cell subset that protects against chronic infection and cancer. Immunity 51, 1028\u20131042 e1024 (2019).","journal-title":"Immunity"},{"key":"58369_CR31","doi-asserted-by":"crossref","unstructured":"Espinosa-Carrasco G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202\u20131216.e8 (2024).","DOI":"10.1016\/j.ccell.2024.05.025"},{"key":"58369_CR32","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1084\/jem.184.6.2207","volume":"184","author":"RF Wang","year":"1996","unstructured":"Wang, R. F., Appella, E., Kawakami, Y., Kang, X. & Rosenberg, S. A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184, 2207\u20132216 (1996).","journal-title":"J. Exp. Med."},{"key":"58369_CR33","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1158\/0008-5472.CAN-17-3303","volume":"78","author":"E Sakai","year":"2018","unstructured":"Sakai, E. et al. Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer. Cancer Res. 78, 1334\u20131346 (2018).","journal-title":"Cancer Res."},{"key":"58369_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","volume":"8","author":"J Hundal","year":"2020","unstructured":"Hundal, J. et al. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol. Res. 8, 409\u2013420 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"58369_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","volume":"9","author":"LP Richman","year":"2019","unstructured":"Richman, L. P., Vonderheide, R. H. & Rech, A. J. Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade. Cell Syst. 9, 375\u2013382 e374 (2019).","journal-title":"Cell Syst."},{"key":"58369_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bfgp\/elac044","volume":"22","author":"T Sundell","year":"2022","unstructured":"Sundell, T. et al. Single-cell RNA sequencing analyses: interference by the genes that encode the B-cell and T-cell receptors. Brief. Funct. Genomics 22, 263\u2013273 (2022).","journal-title":"Brief. Funct. Genomics"},{"key":"58369_CR37","doi-asserted-by":"crossref","unstructured":"Browaeys R. et al. MultiNicheNet: a flexible framework for differential cell-cell communication analysis from multi-sample multi-condition single-cell transcriptomics data. bioRxiv, https:\/\/www.biorxiv.org\/content\/10.1101\/2023.06.13.544751v1 (2023).","DOI":"10.1101\/2023.06.13.544751"},{"key":"58369_CR38","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massague, J. Transforming growth factor-beta signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"58369_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21620-7","volume":"12","author":"N Suryadevara","year":"2022","unstructured":"Suryadevara, N. et al. A molecular signature of lung-resident CD8(+) T cells elicited by subunit vaccination. Sci. Rep. 12, 19101 (2022).","journal-title":"Sci. Rep."},{"key":"58369_CR40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma, S., Caligiuri MA & Yu, J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol. 43, 833\u2013847 (2022).","journal-title":"Trends Immunol."},{"key":"58369_CR41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s42003-020-0916-2","volume":"3","author":"J Waaler","year":"2020","unstructured":"Waaler, J. et al. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models. Commun. Biol. 3, 196 (2020).","journal-title":"Commun. Biol."},{"key":"58369_CR42","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc. Natl. Acad. Sci. USA 105, 15016\u201315021 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"58369_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41586-022-05105-1","volume":"609","author":"C Tsui","year":"2022","unstructured":"Tsui, C. et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature 609, 354\u2013360 (2022).","journal-title":"Nature"},{"key":"58369_CR44","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","volume":"574","author":"AP Benechet","year":"2019","unstructured":"Benechet, A. P. et al. Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Nature 574, 200\u2013205 (2019).","journal-title":"Nature"},{"key":"58369_CR45","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/sj.mt.6300180","volume":"15","author":"T Kimura","year":"2007","unstructured":"Kimura, T. et al. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol. Ther. 15, 1390\u20131399 (2007).","journal-title":"Mol. Ther."},{"key":"58369_CR46","doi-asserted-by":"crossref","unstructured":"Gola A. et al. Prime and target immunization protects against liver-stage malaria in mice. Sci. Transl. Med. 10, eaap9128 (2018).","DOI":"10.1126\/scitranslmed.aap9128"},{"key":"58369_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1116299","volume":"14","author":"S Nakamae","year":"2023","unstructured":"Nakamae, S. et al. Induction of liver-resident memory T cells and protection at liver-stage malaria by mRNA-containing lipid nanoparticles. Front. Immunol. 14, 1116299 (2023).","journal-title":"Front. Immunol."},{"key":"58369_CR48","doi-asserted-by":"crossref","unstructured":"Beck J. D. et al. Long-lasting mRNA-encoded interleukin-2 restores CD8(+) T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell 42, 568-582.e11 (2024).","DOI":"10.1016\/j.ccell.2024.02.013"},{"key":"58369_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1542","volume":"14","author":"G Giacca","year":"2024","unstructured":"Giacca, G., Naldini, L. & Squadrito, M. L. Harnessing lentiviral vectors for in vivo gene therapy of liver metastases. Clin. Transl. Med. 14, e1542 (2024).","journal-title":"Clin. Transl. Med."},{"key":"58369_CR50","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.3389\/fimmu.2019.03016","volume":"10","author":"L Carretero-Iglesia","year":"2019","unstructured":"Carretero-Iglesia, L. et al. High peptide dose vaccination promotes the early selection of tumor antigen-specific CD8 T-cells of enhanced functional competence. Front. Immunol. 10, 3016 (2019).","journal-title":"Front. Immunol."},{"key":"58369_CR51","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct. Target. Ther. 8, 450 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"58369_CR52","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1084\/jem.20150598","volume":"213","author":"DT Utzschneider","year":"2016","unstructured":"Utzschneider, D. T. et al. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. J. Exp. Med. 213, 1819\u20131834 (2016).","journal-title":"J. Exp. Med."},{"key":"58369_CR53","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"58369_CR54","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41590-022-01219-w","volume":"23","author":"D Zehn","year":"2022","unstructured":"Zehn, D., Thimme, R., Lugli, E., de Almeida, G. P. & Oxenius, A. Stem-like\u2019 precursors are the fount to sustain persistent CD8(+) T cell responses. Nat. Immunol. 23, 836\u2013847 (2022).","journal-title":"Nat. Immunol."},{"key":"58369_CR55","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/eji.201242852","volume":"42","author":"EI Zuniga","year":"2012","unstructured":"Zuniga, E. I. & Harker, J. A. T-cell exhaustion due to persistent antigen: quantity not quality? Eur. J. Immunol. 42, 2285\u20132289 (2012).","journal-title":"Eur. J. Immunol."},{"key":"58369_CR56","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"58369_CR57","doi-asserted-by":"crossref","unstructured":"Dolina J. S. et al. Linked CD4+\/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression. J. Clin. Investig. 133 (2023).","DOI":"10.1172\/JCI164258"},{"key":"58369_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"58369_CR59","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.immuni.2023.05.009","volume":"56","author":"M Strazar","year":"2023","unstructured":"Strazar, M. et al. HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery. Immunity 56, 1681\u20131698 e1613 (2023).","journal-title":"Immunity"},{"key":"58369_CR60","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/j.immuni.2023.09.004","volume":"56","author":"E Ghorani","year":"2023","unstructured":"Ghorani, E., Swanton, C. & Quezada, S. A. Cancer cell-intrinsic mechanisms driving acquired immune tolerance. Immunity 56, 2270\u20132295 (2023).","journal-title":"Immunity"},{"key":"58369_CR61","doi-asserted-by":"crossref","unstructured":"Hong Y. et al. Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. JCI Insight 7, e157448 (2022).","DOI":"10.1172\/jci.insight.157448"},{"key":"58369_CR62","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.immuni.2022.07.021","volume":"55","author":"CS Garris","year":"2022","unstructured":"Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. Immunity 55, 1749 (2022).","journal-title":"Immunity"},{"key":"58369_CR63","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","volume":"184","author":"S Kaczanowska","year":"2021","unstructured":"Kaczanowska, S. et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell 184, 2033\u20132052 e2021 (2021).","journal-title":"Cell"},{"key":"58369_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl4106","volume":"14","author":"F Birocchi","year":"2022","unstructured":"Birocchi, F. et al. Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models. Sci. Transl. Med. 14, eabl4106 (2022).","journal-title":"Sci. Transl. Med."},{"key":"58369_CR65","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","volume":"5","author":"A Ghasemi","year":"2024","unstructured":"Ghasemi, A. et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat. Cancer 5, 240\u2013261 (2024).","journal-title":"Nat. Cancer"},{"key":"58369_CR66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","volume":"25","author":"J Strauss","year":"2019","unstructured":"Strauss, J. et al. First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors. Clin. Cancer Res. 25, 99\u2013109 (2019).","journal-title":"Clin. Cancer Res."},{"key":"58369_CR67","doi-asserted-by":"crossref","unstructured":"Momin N. et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci. Transl. Med. 11, eaaw2614 (2019).","DOI":"10.1126\/scitranslmed.aaw2614"},{"key":"58369_CR68","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/mt.2012.10","volume":"20","author":"WY Pan","year":"2012","unstructured":"Pan, W. Y. et al. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol. Ther. 20, 927\u2013937 (2012).","journal-title":"Mol. Ther."},{"key":"58369_CR69","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.omtm.2020.10.009","volume":"19","author":"M Soldi","year":"2020","unstructured":"Soldi, M. et al. Laboratory-scale lentiviral vector production and purification for enhanced ex vivo and in vivo genetic engineering. Mol. Ther. Methods Clin. Dev. 19, 411\u2013425 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"58369_CR70","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.immuni.2021.05.016","volume":"54","author":"F Cilenti","year":"2021","unstructured":"Cilenti, F. et al. A PGE(2)-MEF2A axis enables context-dependent control of inflammatory gene expression. Immunity 54, 1665\u20131682 e1614 (2021).","journal-title":"Immunity"},{"key":"58369_CR71","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670\u2013684 (2007).","journal-title":"Immunity"},{"key":"58369_CR72","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","volume":"168","author":"W Hugo","year":"2017","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 168, 542 (2017).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58369-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58369-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58369-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T17:06:15Z","timestamp":1744391175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58369-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58369"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58369-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L.S., L.N., M.N., and T.K. are inventors on a patent on KC-directed gene transfer, and L.N. is an inventor on patents on miRNA-regulated LV technology filed and managed by the San Raffaele Scientific Institute and the Telethon Foundation. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3471"}}